Beyond Magic Mushrooms: Positive Clinical Trial For Treatment-Resistant Depression & Alcoholism
Psychedelics M&A: Beckley Psytech Acquires Eleusis Therapeutics, Strengthening Drug Pipeline And R&D Team
Palo Santo Closes $50M Psychedelic Therapeutics Investment Fund
Psyched: UK Streamlines MDMA Therapy, FDA OKs MindMed's First LSD Trial In 40 years, Atai Launches Subsidiary
Beckley Psytech Recent News
Beckley Psytech Begins Training Therapists For Phase 2 Trial With Toad Venom, 5-MeO-DMT
Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Up
Beckley Psytech Reaches $100M Financing To Study 5-MeO-DMT, Psilocybin And Other Psychedelics
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
Psychedelic Compound 5-MeO-DMT Could Make Therapy Short And Effective: Beckley Psytech Is 'All In'
Psyched: The First Psychedelics ETF, Beckley Raises $19M, 3 Companies Go Public
'Psyched': Atai Buys Kures, Beckley Psytech Raises $3.7M, Mydecine Acquires NeuroPharma